Filing Flows › Comparisons › BBIO vs CORT
BridgeBio Pharma vs Corcept Therapeutics: BBIO and CORT compared
BridgeBio Pharma is the larger company: $353M of revenue in its latest quarter (Q3 2026) against $340M for Corcept Therapeutics (Q3 2026). BridgeBio Pharma is growing faster (+193% against +64% a year earlier). Corcept Therapeutics is more profitable, with an operating margin of 33.7% against -3.3%.
Where the money goes: BBIO and CORT
BridgeBio Pharma (BBIO) · Q3 2026
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
Corcept Therapeutics (CORT) · Q3 2026
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $353M | $340M |
| Revenue growth, Y/Y | +193% | +64% |
| Operating margin | -3.3% | 33.7% |
| Net earnings | −$60.5M | $127M |
| Net margin | -17.1% | 37.2% |
| Operating cash flow | −$44.2M | $143M |
| Free cash flow | — | $142M |
| Market value | $14.6B | $9.0B |
| P/E | — | 57.3× |
| Analysts’ mean target | $106.85 | $142.60 |
Where the revenue comes from
BridgeBio Pharma
- Net product revenue: $253M (72%)
- License and services revenue: $79.3M (22%)
- Royalty revenue: $20.5M (6%)
Corcept Therapeutics
- Hypercortisolism Products: $249M (73%)
- Lifyorli: $91.4M (27%)
Questions
Which is bigger, BridgeBio Pharma or Corcept Therapeutics?
BridgeBio Pharma is the larger company: $353M of revenue in its latest quarter (Q3 2026) against $340M for Corcept Therapeutics (Q3 2026).
Is BridgeBio Pharma or Corcept Therapeutics growing faster?
BridgeBio Pharma is growing faster (+193% against +64% a year earlier).
Which is more profitable, BridgeBio Pharma or Corcept Therapeutics?
Corcept Therapeutics is more profitable, with an operating margin of 33.7% against -3.3%.
More: BridgeBio Pharma earnings · how BridgeBio Pharma makes money · Corcept Therapeutics earnings · how Corcept Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.